Nursing education
PARP Inhibitors and Ovarian Cancer
Before poly (adenosine diphosphate-ribose) polymerase inhibitors were approved for ovarian cancer, traditional treatment consisted of surgical cytoreduction and platinum-based chemotherapy with a taxane, with or without bevacizumab, depending on stage and type. With the surgery-chemotherapy combination, 70%–75% of patients had recurrence and overall five-year survival rate were 29%, indicating a need for additional therapies.
Share Your Best Practices and Other Oncology Nursing Experiences Through an ONS Voice Article or Video
You and your colleagues innovate every day—providing individual patient cases, developing best practices, and collaborating on other shared experiences. ONS Voice articles and its new video series, My Practice, can help you disseminate your expertise and guidance to other oncology nurses. Tell us your topic ideas, and ONS Publications staff will help you either write an article or create a video resource illustrating your experience.